Yen et al. reported high level of expression of SET and CIP2A, another endogenous inhibitor of PP2A, but decreased levels of PPP2R1A (a structural subunit of PP2A) in colorectal cancers and endometrial cancers displaying MSI, a genetic hallmark of MMR defects [51]. The gene discussed is PTPA; the disease is endometrial cancer.